Slate Path Capital

Concentrated Equity Fund

Long / ShortAUM $6.73BPositions 44Q1 2026

🏆 Clone Portfolio Track Record

Rank #1 of 69 by 3-year alpha vs SPY · mechanically replicating this book, rebalanced at filing dates

A strong clone record is a track record, not a forecast — tested across a decade it doesn't reliably repeat. See what actually holds up →

Analyst Take · Q1 2026

AI

Slate Path tops our clone rankings (#1 of 59, +43.8pt alpha). This quarter it took profits in semis (ON −26%) and energy (EXE −92%, EQT −38%) while opening a $520M TXN position — instantly 7.7% of the book — plus new RIG and SAIA. The book stays tech-heavy (41%) with a contrarian industrial bent.

Generated quarterly from the filing data itself — holdings, changes, sector mix and clone-performance rank. Not investment advice.

Slate Path Capital is a concentrated, research-driven equity fund run by Tiger-lineage investors. Because the book is highly focused, its results — and any mechanical clone of it — can swing sharply on just a few large positions.